Clinical Trial Update: Efficacy and Safety of Factor VIIa on Rebleeding After Surgery for Spontaneous Intracerebral Hemorrhage (ICH) [Phase 2]

View source ↗

Summary

Phase 2 trial results evaluating recombinant activated factor VII (NovoSeven) for reducing rebleeding after surgery in spontaneous intracerebral hemorrhage, wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intracerebral Hemorrhage

Drugs mentioned

• NovoSeven (recombinant coagulation factor VIIa)

Snippet

Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia | Conditions: Intracerebral Hemorrhage | Phase 2 | Status: COMPLETED